Kiora Pharmaceuticals, Inc. (NasdaqCM: KPRX)
Health Care · Pharmaceuticals · US
$2.54
-0.78% today · -5.9% 1Y
Kiora Pharmaceuticals, Inc. (NasdaqCM: KPRX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $16.16M and employs 13 people.
Over the last twelve months the share price has lost 5.9%, trading between 1.76 and 2.91.
Tweenvest scores Kiora Pharmaceuticals, Inc. across four factors: quality 75/100, value 70/100. Its strongest factor is quality.
KPRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.16M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.30
- Dividend yield
- —
- Beta (5Y)
- -0.21
- 52-week high
- $2.91
- 52-week low
- $1.76
- Avg volume (3M)
- —
- Shares outstanding
- 6.36M
- Employees
- 13
- Next earnings
- —
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
- ISIN
- US49721T5074
- Founded
- 1998
- Listed since
- Feb 13, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kimia Biosciences LimitedBSE: 530313 | $16.67M | Rs34.10 | +10.00% |
| PuraPharm Corporation LimitedSEHK: 1498 | $16.50M | HK$0.24 | -5.10% |
| MFC Co., Ltd.KOSE: A432980 | $16.33M | ₩2,555.00 | -2.11% |
| Rocket One Inc.NasdaqCM: RKTO | $16.17M | $0.65 | -6.94% |
| Devonian Health Group Inc.TSXV: GSD | $16.08M | CA$8.25 | +3.13% |
| Peak Processing LimitedASX: PKP | $15.83M | AU$0.02 | +6.25% |
| Otsuka Pakistan LimitedKASE: OTSU | $15.72M | PKRs359.78 | +0.79% |
| Bal Pharma LimitedBSE: 524824 | $15.32M | Rs93.15 | -11.79% |
Figures last refreshed Oct 11, 2026.